Abstract
The fetus may be exposed to increased endogenous or synthetic glucocorticoid (GS) exposure in late gestation. Approximately 7% of pregnant women in Europe and North America are treated with synthetic GSs to promote lung maturation in fetuses at risk of preterm delivery. Maternal steroid treatment before preterm delivery is one of the best documented and most cost effective life saving treatments in prenatal medicine but, in certain circumstances, the price of accelerated lung maturity may be loss of brain cells, increased neurodevelopmental disability, intra-uterine growth restriction (IUGR), and an increased risk of preterm delivery, of programming of post-natal hypertension, and of increased postnatal activity in the hypothalamo-pituitary-adrenal (HPA) axis. Placental 11β-hydroxysteroid dehydrogenase type 2 (11β- HSD2) is the key enzyme which protects the fetus from overexposure to GSs by their oxidation into inactive derivates. We review the evidence for the metabolism of GSs during pregnancy and how endogenous and synthetic GSs cause other changes in the placenta which affect fetal development.
Keywords: Antenatal exposure, glucocorticoids, 11β-hydroxysteroid dehydrogenase, metabolism, placental transport, pregnancy, fetus, synthetic glucocorticoid, steroid treatment, increased neurodevelopmental disability, intra-uterine growth restriction (IUGR), hypothalamo-pituitary-adrenal, fetal development
Current Pharmaceutical Biotechnology
Title: Glucocorticoids in Pregnancy
Volume: 12 Issue: 5
Author(s): Beata Marciniak, Jolanta Patro-Malysza, Elzbieta Poniedzialek-Czajkowska, Zaneta Kimber-Trojnar, Bozena Leszczynska-Gorzelak and Jan Oleszczuk
Affiliation:
Keywords: Antenatal exposure, glucocorticoids, 11β-hydroxysteroid dehydrogenase, metabolism, placental transport, pregnancy, fetus, synthetic glucocorticoid, steroid treatment, increased neurodevelopmental disability, intra-uterine growth restriction (IUGR), hypothalamo-pituitary-adrenal, fetal development
Abstract: The fetus may be exposed to increased endogenous or synthetic glucocorticoid (GS) exposure in late gestation. Approximately 7% of pregnant women in Europe and North America are treated with synthetic GSs to promote lung maturation in fetuses at risk of preterm delivery. Maternal steroid treatment before preterm delivery is one of the best documented and most cost effective life saving treatments in prenatal medicine but, in certain circumstances, the price of accelerated lung maturity may be loss of brain cells, increased neurodevelopmental disability, intra-uterine growth restriction (IUGR), and an increased risk of preterm delivery, of programming of post-natal hypertension, and of increased postnatal activity in the hypothalamo-pituitary-adrenal (HPA) axis. Placental 11β-hydroxysteroid dehydrogenase type 2 (11β- HSD2) is the key enzyme which protects the fetus from overexposure to GSs by their oxidation into inactive derivates. We review the evidence for the metabolism of GSs during pregnancy and how endogenous and synthetic GSs cause other changes in the placenta which affect fetal development.
Export Options
About this article
Cite this article as:
Marciniak Beata, Patro-Malysza Jolanta, Poniedzialek-Czajkowska Elzbieta, Kimber-Trojnar Zaneta, Leszczynska-Gorzelak Bozena and Oleszczuk Jan, Glucocorticoids in Pregnancy, Current Pharmaceutical Biotechnology 2011; 12 (5) . https://dx.doi.org/10.2174/138920111795470868
DOI https://dx.doi.org/10.2174/138920111795470868 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Machine Learning and Artificial Intelligence for Medical Data Analysis and Human Information Analysis in Healthcare
The intersection of machine learning (ML) and artificial intelligence (AI) with the pharmaceutical industry is revolutionizing traditional paradigms in drug discovery and development. These technologies have introduced innovative approaches to analyzing complex datasets and predicting chemical properties, leading to more efficient identification and optimization of drug candidates. By employing sophisticated ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Levosimendan Preoperative
Current Pharmaceutical Design Biomarkers Determining Prognosis of Atrial Fibrillation Ablation
Current Medicinal Chemistry Treatment of Leukoaraiosis: A Futuristic View
Current Drug Targets Missed Opportunities in Type 2 Diabetes Mellitus: A Narrative Review
Current Diabetes Reviews Expression, Purification, and Characterization of an Enzymatically Active Truncated Human Rho-Kinase I (ROCK I) Domain Expressed in Sf-9 Insect Cells
Protein & Peptide Letters An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy
Medicinal Chemistry Integrative Control of Gastrointestinal Motility by Nitric Oxide
Current Medicinal Chemistry The Importance of Early Diagnosis and Treatment in Peripheral Arterial Disease: Insights from the PARTNERS and REACH Registries
Current Vascular Pharmacology Factors Affecting 30-Day Mortality in Chinese Patients with Acute Myocardial Infarction: A Registry-Based Cohort Study
Vascular Disease Prevention (Discontinued) MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Alzheimer’s Disease is Associated with Increased Risk of Osteoporosis: The Chongqing Aging Study
Current Alzheimer Research Visceral Fat as Target of Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome
Current Pharmaceutical Design Ezetimibe and Reactive Oxygen Species
Current Vascular Pharmacology Neuroprotection and Behavior Regulation by Adrenomedullin and PAMP as Shown by Conditional Knockout Models
Current Hypertension Reviews Gene-Gene and Gene-Environment Interplay Represent Specific Susceptibility for Different Types of Ischaemic Stroke and Leukoaraiosis
Current Medicinal Chemistry Understanding the Multifaceted Role of Inflammatory Mediators in Ischemic Stroke
Current Medicinal Chemistry The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Current Vascular Pharmacology The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Cerebrovascular and Blood-Brain Barrier Morphology in Spontaneously Hypertensive Rats: Effect of Treatment with Choline Alphoscerate
CNS & Neurological Disorders - Drug Targets Metabolic Syndrome, Dyslipidemia and Regulation of Lipoprotein Metabolism
Current Diabetes Reviews